Day One Biopharmaceuticals, Inc.
DAWN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | 0.32 | 0.11 | 0.02 |
| FCF Yield | -0.80% | -3.18% | -7.71% | -2.65% |
| EV / EBITDA | -28.39 | -21.71 | -19.52 | -16.48 |
| Quality | ||||
| ROIC | -5.30% | -7.47% | -8.44% | -14.23% |
| Gross Margin | 88.74% | 88.90% | 90.62% | 89.79% |
| Cash Conversion Ratio | 0.29 | 0.82 | 1.64 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | 5,112,951.28% | 5,724,875.05% | 5,450,386.73% | 5,080,732.84% |
| Free Cash Flow Growth | 72.76% | 66.08% | -99.87% | -532.21% |
| Safety | ||||
| Net Debt / EBITDA | 1.67 | 1.11 | 0.76 | 1.90 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.63 | 0.58 | 0.81 | 0.90 |
| Cash Conversion Cycle | 63.54 | 86.94 | 84.81 | 44.54 |